Thrombosis is the process of blood clots that form in the artery or veins. In this thrombosis condition, a clot blocks the flow of blood in the affected area and can create serious complications such as myocardial infraction, Strokes atherosclerotic plaque, among others. Deep vein thrombosis is condition clots that occur in leg or pelvis and if the clots broke off and reached to lungs known as pulmonary embolism. According to CDC statistics, approx. 60,000-100,000 American’s die of venous thromboembolism conditions and 0.9 Million population affected each year in the United States. In Europe, every year approx. 544,000 die due to venous thromboembolism. To prevent blood clots, various treatment options are available in the market to treat these conditions. However, current drugs cause life-threatening side effects such as cerebral hemorrhages and neurotoxicity. To overcome the aforementioned problems companies are developing novel therapeutic agents to enhance fibrinolysis conditions. For instance, Daiichi Sankyo Company, Limited announced granted EU approval for its novel oral anticoagulant drug edoxaban used to prevent stroke and systemic embolism conditions in patients with non-valvular atrial fibrillation.
The increase in incidence of venous thromboembolism conditions, the rise in obese population, myocardial infractions, stroke, pulmonary embolism and genetically related disorders are the factors driving the growth of this market over the forecast period. However, due to lack of awareness about venous thromboembolism conditions, side-effects caused due to current drugs are hindering the growth of blood clot prevention over the forecast period.
The launch of novel therapeutic drugs to prevent blood clots in various blood vessels is expected to boost the growth of the market over the forecast period. Based on drug class it is segmented into anticoagulants, fibrinolytic and anti-platelet drugs. Anticoagulants segment is expected to dominate the market due to many of the drugs are off-patented.
By route of administration, global blood clot prevention market is segmented into the oral route and parenteral route. Parenteral route dominates the market over the forecast period owing to availability drugs in parenteral formulation
Based on the distribution channel, global blood clot prevention market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and mail order pharmacies. Among them, hospital pharmacies are projected to have the highest market share over the forecast period.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/14302
Depending on the geographic region, blood clot prevention market is segmented into five key regions: North America, Latin America, Europe, Asia-Pacific and Middle East & Africa. North America is expected to have highest revenue share in blood clot prevention market owing to the high incidence of venous thromboembolism and deaths due to venous thromboembolism. Asia Pacific geography is expected to dominate the market in near future
Some of the key players in blood clot prevention market are Daiichi Sankyo Company, Limited, Janssen Pharmaceutical, Pfizer Inc., Bayer, Boehringer Ingelheim GmbH, Bristol- Meyers Squibb and Portola Pharmaceuticals
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/14302